Search research articles
Contact Us
Filters
Showing results (11-20 of 18) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 18 results.
Plos Genetics
|
October 27, 2011
HIF-VEGF pathways are critical for chronic otitis media in Junbo and Jeff mouse mutants
Michael T Cheeseman, Hayley E Tyrer, Debbie Williams, et al.
Plos Genetics
|
August 15, 2017
A mutation in Nischarin causes otitis media via LIMK1 and NF-κB pathways
Michael Crompton, Tom Purnell, Hayley E Tyrer, et al.
Scientific Reports
|
March 22, 2016
Minocycline as a re-purposed anti-Wolbachia macrofilaricide: superiority compared with doxycycline regimens in a murine infection model of human lymphatic filariasis
Raman Sharma, Ghaith Al Jayoussi, Hayley E Tyrer, et al.
Scientific Reports
|
January 9, 2018
Corrigendum: Minocycline as a re-purposed anti-Wolbachia macrofilaricide: superiority compared with doxycycline regimens in a murine infection model of human lymphatic filariasis
Raman Sharma, Ghaith Aljayyoussi, Hayley E Tyrer, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 29, 2017
Albendazole and antibiotics synergize to deliver short-course anti-<i>Wolbachia</i> curative treatments in preclinical models of filariasis
Joseph D Turner, Raman Sharma, Ghaith Al Jayoussi, et al.
Scientific Reports
|
March 18, 2017
Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis
Ghaith Aljayyoussi, Hayley E Tyrer, Louise Ford, et al.
Scientific Reports
|
January 20, 2018
Author Correction: Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis
Ghaith Aljayyoussi, Hayley E Tyrer, Louise Ford, et al.
Science Translational Medicine
|
March 15, 2019
Preclinical development of an oral anti-<i>Wolbachia</i> macrolide drug for the treatment of lymphatic filariasis and onchocerciasis
Mark J Taylor, Thomas W von Geldern, Louise Ford, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 18) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 18 results.
Plos Genetics
|
October 27, 2011
HIF-VEGF pathways are critical for chronic otitis media in Junbo and Jeff mouse mutants
Michael T Cheeseman, Hayley E Tyrer, Debbie Williams, et al.
Plos Genetics
|
August 15, 2017
A mutation in Nischarin causes otitis media via LIMK1 and NF-κB pathways
Michael Crompton, Tom Purnell, Hayley E Tyrer, et al.
Scientific Reports
|
March 22, 2016
Minocycline as a re-purposed anti-Wolbachia macrofilaricide: superiority compared with doxycycline regimens in a murine infection model of human lymphatic filariasis
Raman Sharma, Ghaith Al Jayoussi, Hayley E Tyrer, et al.
Scientific Reports
|
January 9, 2018
Corrigendum: Minocycline as a re-purposed anti-Wolbachia macrofilaricide: superiority compared with doxycycline regimens in a murine infection model of human lymphatic filariasis
Raman Sharma, Ghaith Aljayyoussi, Hayley E Tyrer, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 29, 2017
Albendazole and antibiotics synergize to deliver short-course anti-<i>Wolbachia</i> curative treatments in preclinical models of filariasis
Joseph D Turner, Raman Sharma, Ghaith Al Jayoussi, et al.
Scientific Reports
|
March 18, 2017
Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis
Ghaith Aljayyoussi, Hayley E Tyrer, Louise Ford, et al.
Scientific Reports
|
January 20, 2018
Author Correction: Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis
Ghaith Aljayyoussi, Hayley E Tyrer, Louise Ford, et al.
Science Translational Medicine
|
March 15, 2019
Preclinical development of an oral anti-<i>Wolbachia</i> macrolide drug for the treatment of lymphatic filariasis and onchocerciasis
Mark J Taylor, Thomas W von Geldern, Louise Ford, et al.
Page
of 2